

Jelle O Barentsz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7355925/publications.pdf>

Version: 2024-02-01

228
papers

25,998
citations

10956

71
h-index

6454

157
g-index

228
all docs

228
docs citations

228
times ranked

12996
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. <i>BJU International</i> , 2022, 129, 480-490.	1.3	5
2	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-Ultrasound Fusion Guided Biopsy Using Local Anesthesia. <i>European Urology</i> , 2022, 81, 110-117.	0.9	17
3	PI-QUAL v.1: the first step towards good-quality prostate MRI. <i>European Radiology</i> , 2022, 32, 876-878.	2.3	10
4	Ferumoxtran-10-enhanced 3-T Magnetic Resonance Angiography of Pelvic Arteries: Initial Experience. <i>European Urology Focus</i> , 2022, 8, 1802-1808.	1.6	5
5	A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men. <i>European Urology</i> , 2022, 82, 318-326.	0.9	9
6	Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer. <i>European Urology Focus</i> , 2022, 8, 1187-1191.	1.6	3
7	An Update to the Pilot Study of ¹⁷⁷ Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	0.7	2
8	Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. <i>Radiology</i> , 2022, 304, 342-350.	3.6	21
9	Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection. <i>European Urology Open Science</i> , 2022, 43, 1-4.	0.2	1
10	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	2.0	37
11	Perspectives and Concerns about PI-RADS and Variability. <i>Radiology</i> , 2021, 298, E112-E112.	3.6	0
12	A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis. <i>European Radiology</i> , 2021, 31, 4386-4389.	2.3	17
13	PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 216, 3-19.	1.0	76
14	Head-to-Head Comparison of ⁶⁸ Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1258-1263.	2.8	26
15	Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 868-876.	2.6	72
16	Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>European Urology</i> , 2021, 79, 327-329.	0.9	54
17	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	3.2	53
18	Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. <i>European Urology Oncology</i> , 2021, 4, 863-865.	2.6	1

#	ARTICLE	IF	CITATIONS
19	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 9567-9578.	2.3	34
20	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1110-1119.	2.0	40
21	Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik van Poppel, René Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021;79:327-329; Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy. <i>European Urology</i> , 2021, 80, e28-e29.	0.9	0
22	A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 731-739.	2.6	51
23	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	0.7	13
24	Radiomic combination of spatial and temporal features extracted from DCE-MRI for prostate cancer detection *. <i>European Urology Oncology</i> , 2021, 2021, 3153-3156.		0
25	Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 967-974.	1.6	15
26	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition. <i>European Urology</i> , 2020, 77, 457-468.	0.9	62
27	Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis. <i>European Urology Oncology</i> , 2020, 3, 32-41.	2.6	53
28	Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?. <i>European Urology Oncology</i> , 2020, 3, 216-223.	2.6	35
29	Reply to Gianfranco Imbriano, Massimo Imbriano, and Renato Ciurlo's Letter to the Editor re: Marlies van der Leest, Bas IsraËl, Eric Bastiaan Cornel, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. <i>Eur Urol</i> 2019;76:574-581. Are We Meeting Our Standards? Stringent Prostate Imaging Reporting and Data System Acquisition Requirements Might be Limiting Prostate Accessibility. <i>European Urology</i> , 2020, 77, e58-e59.	0.9	8
30	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy. <i>European Urology</i> , 2020, 77, 481-490.	0.9	36
31	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. <i>European Urology</i> , 2020, 77, 469-480.	0.9	59
32	Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>European Urology</i> , 2020, 78, 633-636.	0.9	9
33	Lutetium-177-PSMA-Targeted Therapy as Metastases Directed Therapy in Oligometastatic Hormone Sensitive Prostate Cancer, a Randomized Controlled Trial. <i>BMC Cancer</i> , 2020, 20, 884.	1.1	32
34	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. <i>European Radiology</i> , 2020, 30, 5404-5416.	2.3	185
35	Can Biparametric Prostate Magnetic Resonance Imaging Fulfill its PROMIS?. <i>European Urology</i> , 2020, 78, 512-514.	0.9	6
36	Platinum Opinion Counterinterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound. <i>European Urology</i> , 2020, 78, 307-309.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. <i>European Urology Oncology</i> , 2020, 3, 145-167.	2.6	75
38	Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists' Training. <i>European Urology</i> , 2020, 78, 483-485.	0.9	27
39	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>Radiology</i> , 2020, 296, 76-84.	3.6	207
40	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. , 2020, 30, 5404.		1
41	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. <i>European Urology</i> , 2019, 75, 385-396.	0.9	200
42	Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial. <i>European Urology Oncology</i> , 2019, 2, 617-624.	2.6	46
43	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
44	Reply to Jochen Walz. Let's Keep It at One Step at a Time: Why Biparametric Magnetic Resonance Imaging Is Not the Priority Today. <i>Eur Urol</i> 2019;76:582-3. <i>European Urology</i> , 2019, 76, 584-585.	0.9	4
45	USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience. <i>European Radiology</i> , 2019, 29, 6529-6538.	2.3	17
46	Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. <i>Eur Urol</i> 2019;76:329-40. <i>European Urology</i> , 2019, 76, e79.	0.9	0
47	Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men. <i>BJU International</i> , 2019, 124, 775-784.	1.3	31
48	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. <i>European Urology</i> , 2019, 76, 574-581.	0.9	114
49	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. <i>Radiology</i> , 2019, 292, 464-474.	3.6	162
50	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. <i>European Urology</i> , 2019, 76, 340-351.	0.9	1,270
51	Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss. <i>European Urology</i> , 2019, 75, 721-722.	0.9	12
52	The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. <i>European Urology</i> , 2019, 75, 582-590.	0.9	188
53	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. <i>European Urology</i> . 2019, 75, 570-578.	0.9	521
54	Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). <i>Eur Urol</i> 2018;74:294-306. <i>European Urology</i> , 2019, 75, e29-e30.	0.9	3

#	ARTICLE	IF	CITATIONS
55	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	1.6	23
56	Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. <i>European Urology</i> , 2018, 73, 353-360.	0.9	105
57	Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2018, 10, e1471.	3.3	70
58	Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?. <i>European Urology</i> , 2018, 73, 343-350.	0.9	19
59	Fast 3-T MR-guided transrectal prostate biopsy using an in-room tablet device for needle guide alignment: a feasibility study. <i>European Radiology</i> , 2018, 28, 4824-4831.	2.3	1
60	Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study. <i>American Journal of Roentgenology</i> , 2018, 211, W242-W251.	1.0	7
61	Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). <i>Eur Urol</i> 2018;74:294-306. <i>European Urology</i> , 2018, 74, e109.	0.9	7
62	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	372
63	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 219-219.	0.8	2
64	A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. <i>BJU International</i> , 2017, 120, 774-781.	1.3	98
65	Time to enhancement derived from ultrafast breast MRI as a novel parameter to discriminate benign from malignant breast lesions. <i>European Journal of Radiology</i> , 2017, 89, 90-96.	1.2	66
66	Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. <i>European Urology</i> , 2017, 72, 189-191.	0.9	12
67	Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?. <i>European Urology</i> , 2017, 71, 896-903.	0.9	119
68	MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging. <i>World Journal of Urology</i> , 2017, 35, 703-711.	1.2	42
69	A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. <i>Prostate</i> , 2017, 77, 1401-1407.	1.2	61
70	Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?. <i>European Urology</i> , 2017, 71, 517-531.	0.9	326
71	Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging. <i>European Urology</i> , 2017, 71, 93-95.	0.9	2
72	Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. <i>Eur Urol</i> 2016;69:16-40. <i>European Urology</i> , 2016, 70, e137-e138.	0.9	22

#	ARTICLE	IF	CITATIONS
73	Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy. <i>Clinical Imaging</i> , 2016, 40, 745-750.	0.8	19
74	PI-RADS Version 2: A Pictorial Update. <i>Radiographics</i> , 2016, 36, 1354-1372.	1.4	88
75	MR-targeted TRUS prostate biopsy using local reference augmentation: initial experience. <i>International Urology and Nephrology</i> , 2016, 48, 1037-1045.	0.6	6
76	Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. <i>European Urology</i> , 2016, 69, 41-49.	0.9	454
77	PI-RADS Prostate Imaging â€œ Reporting and Data System: 2015, Version 2. <i>European Urology</i> , 2016, 69, 16-40.	0.9	2,290
78	Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. <i>European Urology</i> , 2016, 70, 233-245.	0.9	466
79	Computer-extracted Features Can Distinguish Noncancerous Confounding Disease from Prostatic Adenocarcinoma at Multiparametric MR Imaging. <i>Radiology</i> , 2016, 278, 135-145.	3.6	43
80	Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol. <i>PeerJ</i> , 2016, 4, e2471.	0.9	8
81	Biomechanical modeling constrained surfaceâ€¢based image registration for prostate MR guided TRUS biopsy. <i>Medical Physics</i> , 2015, 42, 2470-2481.	1.6	18
82	Multiparametric Magnetic Resonance Imaging for Discriminating Low-Grade From High-Grade Prostate Cancer. <i>Investigative Radiology</i> , 2015, 50, 490-497.	3.5	63
83	Will Magnetic Resonance Imaging-guided Biopsy Replace Systematic Biopsy?. <i>European Urology Focus</i> , 2015, 1, 152-155.	1.6	2
84	Reply to Yaalini Shanmugabavan, Stephanie Guillaumier and Hashim U. Ahmed's Letter to the Editor re: Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasoundâ€¢Guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies. <i>Eur Urol</i> 2014;66:22â€¢9. <i>European Urology</i> , 2015, 67, e54-e55.	0.9	8
85	Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasoundâ€¢Guided Biopsy. <i>American Journal of Roentgenology</i> , 2015, 205, 57-63.	1.0	26
86	Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging. <i>Radiology</i> , 2015, 276, 479-489.	3.6	53
87	Can imaging accurately diagnose lymph node involvement?. <i>Nature Reviews Urology</i> , 2015, 12, 313-315.	1.9	9
88	Clinical evaluation of a computer-aided diagnosis system for determining cancer aggressiveness in prostate MRI. <i>European Radiology</i> , 2015, 25, 3187-3199.	2.3	57
89	Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. <i>European Urology</i> , 2015, 67, 1112-1121.	0.9	270
90	Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e19-69.e28.	0.8	58

#	ARTICLE	IF	CITATIONS
91	Standardization of Multiparametric Prostate MR Imaging Using PI-RADS. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	29
92	Automated Real-time Needle-Guide Tracking for Fast 3-T MR-guided Transrectal Prostate Biopsy: A Feasibility Study. <i>Radiology</i> , 2014, 273, 879-886.	3.6	20
93	Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonance-guided Biopsy for Early Risk Restratification in Active Surveillance of Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2014, 49, 165-172.	3.5	83
94	Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. <i>European Urology</i> , 2014, 66, 430-436.	0.9	171
95	Lymphotropic Nanoparticle-enhanced MRI in Prostate Cancer: Value and Therapeutic Potential. <i>Current Urology Reports</i> , 2014, 15, 389.	1.0	38
96	Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound-guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies. <i>European Urology</i> , 2014, 66, 22-29.	0.9	445
97	Computer-Aided Detection of Prostate Cancer in MRI. <i>IEEE Transactions on Medical Imaging</i> , 2014, 33, 1083-1092.	5.4	338
98	Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis. <i>American Journal of Roentgenology</i> , 2014, 202, 343-351.	1.0	402
99	Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer. <i>European Radiology</i> , 2014, 24, 2597-2605.	2.3	38
100	Image quality and cancer visibility of T2-weighted Magnetic Resonance Imaging of the prostate at 7 Tesla. <i>European Radiology</i> , 2014, 24, 1950-1958.	2.3	32
101	Prostate Cancer Antigen 3: Diagnostic Outcomes in Men Presenting With Urinary Prostate Cancer Antigen 3 Scores ≥ 100 . <i>Urology</i> , 2014, 83, 613-616. Reply to Sarah Willis, Alec Miners, and Jan van der Meulen's Letter to the Editor re: Maarten de Rooij, Simone Crienen, J. Alfred Witjes, Jelle O. Barentsz, Maroeska M. Rovers, Janneke P.C. Grutters.	0.5	14
102	Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2013.12.012 . <i>European Urology</i> , 2014, 66, e30.	0.9	2
103	Prostate MRI: Access to and Current Practice of Prostate MRI in the United States. <i>Journal of the American College of Radiology</i> , 2014, 11, 156-160.	0.9	52
104	Multiparametric magnetic resonance imaging of the prostate: current concepts. <i>Radiologia Brasileira</i> , 2014, 47, 292-300.	0.3	20
105	MRI-Guided Biopsy for Prostate Cancer Detection: A Systematic Review of Current Clinical Results. <i>Current Urology Reports</i> , 2013, 14, 209-213.	1.0	86
106	A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured. <i>Radiation Oncology</i> , 2013, 8, 190.	1.2	11
107	Reply to Letter to the Editor re: ESUR prostate MR guidelines. <i>European Radiology</i> , 2013, 23, 2322-2323.	2.3	6
108	Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies. <i>European Radiology</i> , 2013, 23, 1401-1407.	2.3	41

#	ARTICLE	IF	CITATIONS
109	Corrigendum to “Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients” [Radiother Oncol 106 (2013) 59–63]. Radiotherapy and Oncology, 2013, 107, 442.	0.3	0
110	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 281-284.	0.8	32
111	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. Journal of Magnetic Resonance Imaging, 2013, 37, 48-58.	1.9	119
112	Assessment of Prostate Cancer Aggressiveness Using Dynamic Contrast-enhanced Magnetic Resonance Imaging at 3 T. European Urology, 2013, 64, 448-455.	0.9	152
113	Comments on Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer, Triantafyllou et al., European journal of cancer, published online 22 October 2012. European Journal of Cancer, 2013, 49, 1789-1790.	1.3	7
114	Ferumoxtran-10 Ultrasmall Superparamagnetic Iron Oxide–Enhanced Diffusion-weighted Imaging Magnetic Resonance Imaging for Detection of Metastases in Normal-sized Lymph Nodes in Patients with Bladder and Prostate Cancer: Do We Enter the Era After Extended Pelvic Lymph Node Dissection?. European Urology, 2013, 64, 961-963.	0.9	27
115	Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiotherapy and Oncology, 2013, 106, 59-63.	0.3	42
116	Individualized image-based lymph node irradiation for prostate cancer. Nature Reviews Urology, 2013, 10, 376-385.	1.9	10
117	Microvasculature in transition zone prostate tumors resembles normal prostatic tissue. Prostate, 2013, 73, 467-475.	1.2	22
118	Surface-based prostate registration with biomechanical regularization. , 2013, , .		2
119	Prostate Cancer: Computer-aided Diagnosis with Multiparametric 3-T MR Imaging—Effect on Observer Performance. Radiology, 2013, 266, 521-530.	3.6	103
120	MR Imaging–guided Focal Cryoablation in Patients with Recurrent Prostate Cancer. Radiology, 2013, 268, 451-460.	3.6	59
121	Transition Zone Prostate Cancer: Detection and Localization with 3-T Multiparametric MR Imaging. Radiology, 2013, 266, 207-217.	3.6	222
122	Differentiation of Prostatitis and Prostate Cancer by Using Diffusion-weighted MR Imaging and MR-guided Biopsy at 3 T. Radiology, 2013, 267, 164-172.	3.6	105
123	Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. International Journal of Molecular Sciences, 2013, 14, 11347-11355.	1.8	25
124	Diffusion-Weighted Magnetic Resonance Imaging in the Prostate Transition Zone. Investigative Radiology, 2013, 48, 693-701.	3.5	46
125	MRI/US-guided biopsy—a viable alternative to TRUS-guidance. Nature Reviews Urology, 2013, 10, 559-560.	1.9	13
126	Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing. Family Practice, 2013, 30, 648-654.	0.8	15

#	ARTICLE	IF	CITATIONS
127	Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2013, 48, 152-157.	3.5	63
128	Molecular and Functional Imaging for Detection of Lymph Node Metastases in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13842-13857.	1.8	28
129	MRI-guided and robotic-assisted prostate biopsy. <i>Current Opinion in Urology</i> , 2012, 22, 316-319.	0.9	30
130	Prostate Cancer Aggressiveness: In Vivo Assessment of MR Spectroscopy and Diffusion-weighted Imaging at 3 T. <i>Radiology</i> , 2012, 265, 457-467.	3.6	127
131	Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score $\geq 3 + 3 = 6$ Upon Schematic TRUS-Guided Biopsy. <i>Investigative Radiology</i> , 2012, 47, 153-158.	3.5	65
132	MRI-Guided Interventions for the Treatment of Prostate Cancer. <i>American Journal of Roentgenology</i> , 2012, 199, 714-720.	1.0	37
133	Three-Tesla Magnetic Resonance-Guided Prostate Biopsy in Men With Increased Prostate-Specific Antigen and Repeated, Negative, Random, Systematic, Transrectal Ultrasound Biopsies: Detection of Clinically Significant Prostate Cancers. <i>European Urology</i> , 2012, 62, 902-909.	0.9	204
134	Magnetic Resonance Lymphography-Guided Selective High-Dose Lymph Node Irradiation in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 175-183.	0.4	19
135	High Occurrence of Aberrant Lymph Node Spread on Magnetic Resonance Lymphography in Prostate Cancer Patients With a Biochemical Recurrence After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1405-1410.	0.4	35
136	Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients With Lymph Node Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 712-718.	0.4	45
137	Magnetic Resonance Lymphography Findings in Patients With Biochemical Recurrence After Prostatectomy and the Relation With the Stephenson Nomogram. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1186-1191.	0.4	8
138	Interpatient Variation in Normal Peripheral Zone Apparent Diffusion Coefficient: Effect on the Prediction of Prostate Cancer Aggressiveness. <i>Radiology</i> , 2012, 265, 260-266.	3.6	66
139	High-risk prostate cancer: value of multi-modality 3T MRI-guided biopsies after previous negative biopsies. <i>Abdominal Radiology</i> , 2012, 37, 892-896.	1.0	14
140	Computer aided analysis of breast MRI enhancement kinetics using mean shift clustering and multifeature iterative region of interest selection. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 1104-1112.	1.9	5
141	Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. <i>European Radiology</i> , 2012, 22, 468-475.	2.3	104
142	MR-guided breast biopsy at 3T: diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy. <i>European Radiology</i> , 2012, 22, 341-349.	2.3	24
143	ESUR prostate MR guidelines 2012. <i>European Radiology</i> , 2012, 22, 746-757.	2.3	2,176
144	Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. <i>BJU International</i> , 2012, 109, 1-7.	1.3	17

#	ARTICLE	IF	CITATIONS
145	Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imagingâ€“Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort. <i>European Urology</i> , 2012, 61, 177-184.	0.9	277
146	Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. <i>BJU International</i> , 2012, 110, 942-948.	1.3	77
147	Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 20-31.	1.9	49
148	Reproducibility of 3D ¹ H MR spectroscopic imaging of the prostate at 1.5T. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 166-173.	1.9	15
149	Value of multimodality MRI and MR-guided biopsy at inclusion in an active surveillance protocol for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 105-105.	0.8	0
150	Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging. <i>Radiology</i> , 2011, 261, 46-66.	3.6	618
151	MRI-guided breast biopsy at 3T using a dedicated large core biopsy set: Feasibility and initial results. <i>European Journal of Radiology</i> , 2011, 79, 257-261.	1.2	23
152	Initial Results of 3-Dimensional 1H-Magnetic Resonance Spectroscopic Imaging in the Localization of Prostate Cancer at 3 Tesla. <i>Investigative Radiology</i> , 2011, 46, 301-306.	3.5	21
153	Discriminating Cancer From Noncancer Tissue in the Prostate by 3-Dimensional Proton Magnetic Resonance Spectroscopic Imaging. <i>Investigative Radiology</i> , 2011, 46, 25-33.	3.5	67
154	Prostate Cancer Detection and Dutasteride: Utility and Limitations of Prostate-Specific Antigen in Men with Previous Negative Biopsies. <i>European Urology</i> , 2011, 59, 183-190.	0.9	12
155	Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting. <i>European Urology</i> , 2011, 59, 477-494.	0.9	642
156	Advances in Magnetic Resonance Imaging: How They Are Changing the Management of Prostate Cancer. <i>European Urology</i> , 2011, 59, 962-977.	0.9	225
157	In Vivo Assessment of Prostate Cancer Aggressiveness Using Magnetic Resonance Spectroscopic Imaging at 3 T with an Endorectal Coil. <i>European Urology</i> , 2011, 60, 1074-1080.	0.9	91
158	Re: Axel Heidenreich. Consensus Criteria for the Use of Magnetic Resonance Imaging in the Diagnosis and Staging of Prostate Cancer: Not Ready for Routine Use. <i>Eur Urol</i> 2011;59:495â€“7. <i>European Urology</i> , 2011, 60, e5-e6.	0.9	1
159	Ferumoxtran-10 MR Lymphography for Target Definition and Follow-up in a Patient Undergoing Image-Guided, Dose-Escalated Radiotherapy of Lymph Nodes upon PSA Relapse. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 206-212.	1.0	15
160	Quantitative analysis of lymph vessel characteristics in organ confined prostate cancer. <i>Prostate</i> , 2011, 71, 91-97.	1.2	3
161	Evaluation of axillary lymph nodes by diffusionâ€“weighted MRI using ultrasmall superparamagnetic iron oxide in patients with breast cancer: Initial clinical experience. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 557-562.	1.9	32
162	Comparison of Nodal Risk Formula and MR Lymphography for Predicting Lymph Node Involvement in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 8-15.	0.4	6

#	ARTICLE	IF	CITATIONS
163	Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. <i>Radiology</i> , 2011, 259, 453-461.	3.6	537
164	State-of-the-art urologic imaging in the diagnosis of prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 25-38.	0.8	36
165	Feasibility of a Pneumatically Actuated MR-compatible Robot for Transrectal Prostate Biopsy Guidance. <i>Radiology</i> , 2011, 260, 241-247.	3.6	80
166	Required Accuracy of MR-US Registration for Prostate Biopsies. <i>Lecture Notes in Computer Science</i> , 2011, , 92-99.	1.0	2
167	Automated classification of lymph nodes in USPIO-enhanced MR-images: a comparison of three segmentation methods. , 2010, , .		0
168	Automated segmentation of reference tissue for prostate cancer localization in dynamic contrast enhanced MRI. <i>Proceedings of SPIE</i> , 2010, , .	0.8	0
169	Feasibility of 3T Dynamic Contrast-Enhanced Magnetic Resonance-Guided Biopsy in Localizing Local Recurrence of Prostate Cancer After External Beam Radiation Therapy. <i>Investigative Radiology</i> , 2010, 45, 121-125.	3.5	56
170	Perineal descent and patients'™ symptoms of anorectal dysfunction, pelvic organ prolapse, and urinary incontinence. <i>International Urogynecology Journal</i> , 2010, 21, 721-729.	0.7	21
171	Magnetic Resonance Imaging of Prostate Cancer. , 2010, , 125-141.		0
172	Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative Biopsies and Increased Prostate Specific Antigen. <i>Journal of Urology</i> , 2010, 183, 520-528.	0.2	344
173	Computer Aided Detection of Prostate Cancer Using T2, DWI and DCE MRI: Methods and Clinical Applications. <i>Lecture Notes in Computer Science</i> , 2010, , 4-14.	1.0	1
174	Imaging modalities for prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 923-937.	1.1	31
175	Prostate Cancer: Detection of Lymph Node Metastases Outside the Routine Surgical Area with Ferumoxtran-10-enhanced MR Imaging. <i>Radiology</i> , 2009, 251, 408-414.	3.6	132
176	In Vivo Imaging of the Aneurysm Wall With MRI and a Macrophage-Specific Contrast Agent. <i>American Journal of Roentgenology</i> , 2009, 193, W437-W441.	1.0	26
177	Cost-effectiveness of MR Lymphography for the Detection of Lymph Node Metastases in Patients with Prostate Cancer. <i>Radiology</i> , 2009, 252, 729-736.	3.6	14
178	Dynamic magnetic resonance imaging: reliability of anatomical landmarks and reference lines used to assess pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2009, 20, 141-148.	0.7	40
179	POP-Q, dynamic MR imaging, and perineal ultrasonography: do they agree in the quantification of female pelvic organ prolapse?. <i>International Urogynecology Journal</i> , 2009, 20, 541-549.	0.7	52
180	A systematic review of clinical studies on dynamic magnetic resonance imaging of pelvic organ prolapse: the use of reference lines and anatomical landmarks. <i>International Urogynecology Journal</i> , 2009, 20, 721-729.	0.7	72

#	ARTICLE	IF	CITATIONS
181	Computerized whole slide quantification shows increased microvascular density in pT2 prostate cancer as compared to normal prostate tissue. <i>Prostate</i> , 2009, 69, 62-69.	1.2	25
182	Changes in Prostate Shape and Volume and Their Implications for Radiotherapy After Introduction of Endorectal Balloon as Determined by MRI at 3T. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1446-1453.	0.4	52
183	Symptoms of pelvic floor dysfunction are poorly correlated with findings on clinical examination and dynamic MR imaging of the pelvic floor. <i>International Urogynecology Journal</i> , 2009, 20, 1169-1174.	0.7	42
184	Editorial Comment on: Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer. <i>European Urology</i> , 2008, 54, 599-600.	0.9	2
185	MR-Guided Biopsy of the Prostate: An Overview of Techniques and a Systematic Review. <i>European Urology</i> , 2008, 54, 517-527.	0.9	148
186	Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. <i>Medical Physics</i> , 2008, 35, 888-899.	1.6	81
187	MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. <i>Lancet Oncology</i> , The, 2008, 9, 850-856.	5.1	285
188	The importance of the extent of pelvic-lymph-node dissection in the diagnosis of lymph-node metastases in prostate cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2008, 9, 917-918.	5.1	4
189	Diffusion and Perfusion MR Imaging of the Prostate. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2008, 16, 685-695.	0.6	73
190	Combining T2-weighted with dynamic MR images for computerized classification of prostate lesions. , 2008, , .		7
191	Thirty-Two-Channel Coil 3T Magnetic Resonance-Guided Biopsies of Prostate Tumor Suspicious Regions Identified on Multimodality 3T Magnetic Resonance Imaging: Technique and Feasibility. <i>Investigative Radiology</i> , 2008, 43, 686-694.	3.5	104
192	Value of 3-T Magnetic Resonance Imaging in Local Staging of Prostate Cancer. <i>Topics in Magnetic Resonance Imaging</i> , 2008, 19, 285-289.	0.7	23
193	Magnetic Resonance-Guided Biopsy of the Prostate. <i>Topics in Magnetic Resonance Imaging</i> , 2008, 19, 291-295.	0.7	27
194	Local staging of Prostate Cancer Using Endorectal Coil Magnetic Resonance Imaging. , 2008, , 641-654.		0
195	Three-dimensional Proton MR Spectroscopy of Human Prostate at 3 T without Endorectal Coil: Feasibility. <i>Radiology</i> , 2007, 245, 507-516.	3.6	122
196	Prostate Cancer: Body-Array versus Endorectal Coil MR Imaging at 3 T – Comparison of Image Quality, Localization, and Staging Performance. <i>Radiology</i> , 2007, 244, 184-195.	3.6	295
197	Effect of calibration on computerized analysis of prostate lesions using quantitative dynamic contrast-enhanced magnetic resonance imaging. , 2007, , .		2
198	Standardized Threshold Approach Using Three-Dimensional Proton Magnetic Resonance Spectroscopic Imaging in Prostate Cancer Localization of the Entire Prostate. <i>Investigative Radiology</i> , 2007, 42, 116-122.	3.5	70

#	ARTICLE	IF	CITATIONS
199	Prostate and Lymph Node Proton Magnetic Resonance (MR) Spectroscopic Imaging with External Array Coils at 3 T to Detect Recurrent Prostate Cancer After Radiation Therapy. <i>Investigative Radiology</i> , 2007, 42, 420-427.	3.5	25
200	Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. <i>European Journal of Radiology</i> , 2007, 63, 369-372.	1.2	59
201	Automated analysis of contrast enhancement in breast MRI lesions using mean shift clustering for ROI selection. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 26, 606-614.	1.9	29
202	Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectalâ€“pelvic phased-array coils. <i>European Radiology</i> , 2007, 17, 1055-1065.	2.3	157
203	Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging. <i>Radiology</i> , 2006, 241, 449-458.	3.6	506
204	IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 291-303.	0.4	168
205	A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. <i>European Radiology</i> , 2006, 16, 927-938.	2.3	89
206	Prostate Cancer Evaluated with Ferumoxtran-10â€“enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: Early Experience. <i>Radiology</i> , 2006, 239, 481-487.	3.6	67
207	Prostate Cancer: Local Staging at 3-T Endorectal MR Imagingâ€“Early Experience. <i>Radiology</i> , 2006, 238, 184-191.	3.6	159
208	Commonly Used Imaging Techniques for Diagnosis and Staging. <i>Journal of Clinical Oncology</i> , 2006, 24, 3234-3244.	0.8	84
209	Magnetic Resonance-Guided Biopsies and Localizations of the Breast. <i>Investigative Radiology</i> , 2005, 40, 379-384.	3.5	37
210	Variability in the Description of Morphologic and Contrast Enhancement Characteristics of Breast Lesions on Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2005, 40, 355-362.	3.5	81
211	Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. <i>Magnetic Resonance in Medicine</i> , 2005, 53, 1268-1274.	1.9	91
212	Staging Prostate Cancer with Dynamic Contrast-enhanced Endorectal MR Imaging prior to Radical Prostatectomy: Experienced versus Less Experienced Readers. <i>Radiology</i> , 2005, 237, 541-549.	3.6	223
213	Intravenous Ferumoxtran-10 MRI: a cellular MR contrast agent with high clinical potential for the detection of small metastases. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 418-420.	2.2	0
214	Prostate Cancer: Precision of Integrating Functional MR Imaging with Radiation Therapy Treatment by Using Fiducial Gold Markers. <i>Radiology</i> , 2005, 236, 311-317.	3.6	58
215	Urinary Bladder Cancer: Preoperative Nodal Staging with Ferumoxtran-10â€“enhanced MR Imaging. <i>Radiology</i> , 2004, 233, 449-456.	3.6	216
216	Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. <i>European Radiology</i> , 2004, 14, 1707-12.	2.3	25

#	ARTICLE	IF	CITATIONS
217	Combined quantitative dynamic contrast-enhanced MR imaging and ¹ H MR spectroscopic imaging of human prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 279-287.	1.9	160
218	Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. <i>Magnetic Resonance in Medicine</i> , 2004, 52, 80-88.	1.9	108
219	Initial Experience of 3 Tesla Endorectal Coil Magnetic Resonance Imaging and ¹ H-Spectroscopic Imaging of the Prostate. <i>Investigative Radiology</i> , 2004, 39, 671-680.	3.5	148
220	Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 2491-2499.	13.9	2,168
221	Discrimination of Prostate Cancer from Normal Peripheral Zone and Central Gland Tissue by Using Dynamic Contrast-enhanced MR Imaging. <i>Radiology</i> , 2003, 229, 248-254.	3.6	375
222	MR Lymphangiography for Detection of Minimal Nodal Disease in Patients with Prostate Cancer. <i>Academic Radiology</i> , 2002, 9, S312-S313.	1.3	30
223	Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. <i>European Radiology</i> , 2002, 12, 2294-2302.	2.3	303
224	Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 13, 607-614.	1.9	106
225	Prostate Cancer Staging: Should MR Imaging Be Used?—A Decision Analytic Approach. <i>Radiology</i> , 2000, 215, 445-451.	3.6	117
226	Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 1999, 10, 295-304.	1.9	133
227	Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. <i>Magnetic Resonance in Medicine</i> , 1997, 37, 204-213.	1.9	87
228	Vascular changes following hip arthroplasty: The femur in goats studied with and without cementation. <i>Acta Orthopaedica</i> , 1988, 59, 643-649.	1.4	17